GBM
MCID: GLB015
MIFTS: 63

Glioblastoma Multiforme (GBM)

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Glioblastoma Multiforme

MalaCards integrated aliases for Glioblastoma Multiforme:

Name: Glioblastoma Multiforme 12 76 55 15 73
Glioblastoma 44 73
Gbm 12 15
Grade Iv Adult Astrocytic Tumor 12
Primary Glioblastoma Multiforme 12
Adult Glioblastoma Multiforme 12
Spongioblastoma Multiforme 12
Primary Glioblastoma 73
Adult Glioblastoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3068
MeSH 44 D005909
SNOMED-CT 68 63634009

Summaries for Glioblastoma Multiforme

Disease Ontology : 12 An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

MalaCards based summary : Glioblastoma Multiforme, also known as glioblastoma, is related to glioblastoma and giant cell glioblastoma, and has symptoms including seizures and headache. An important gene associated with Glioblastoma Multiforme is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Gliadel Wafer and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and testes, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Wikipedia : 76 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins... more...

Related Diseases for Glioblastoma Multiforme

Diseases related to Glioblastoma Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 419)
# Related Disease Score Top Affiliating Genes
1 glioblastoma 33.4 DMBT1 EGFR IDH1 MGMT MIR128-1 MIR137
2 giant cell glioblastoma 33.0 EGFR IDH1 MGMT PTEN TP53
3 grade iii astrocytoma 31.5 DMBT1 EGFR MGMT PDGFRA PTEN TP53
4 gliosarcoma 31.1 EGFR IDH1 MGMT PTEN TP53
5 brain cancer 31.0 DMBT1 EGFR IDH1 MGMT PDGFRA PTEN
6 pleomorphic xanthoastrocytoma 30.9 IDH1 MGMT TP53
7 cytomegalovirus infection 30.8 EGFR MTOR PDGFRA
8 medulloblastoma 30.7 DMBT1 EGFR IDH1 MGMT PDGFRA PTEN
9 gliomatosis cerebri 30.6 EGFR IDH1 PTEN TP53
10 glioma 30.5 DMBT1 EGFR IDH1 MIR21 MIR210 MIR221
11 mixed glioma 30.4 IDH1 PDGFRA TP53
12 small cell carcinoma 30.4 EGFR PDGFRA PTEN TP53
13 oligodendroglioma 30.4 EGFR IDH1 MGMT PDGFRA PTEN TP53
14 small cell cancer of the lung 30.3 EGFR MIR21 PTEN TP53
15 li-fraumeni syndrome 30.2 EGFR IDH1 PTEN TP53
16 adamantinoma of long bones 30.1 EGFR MGMT PTEN TP53
17 anaplastic oligodendroglioma 30.1 EGFR MGMT
18 spinal cord astrocytoma 30.0 IDH1 MGMT TP53
19 pituitary adenoma 29.9 MIR128-1 MIR132 MIR149
20 testicular germ cell tumor 29.7 MIR133B PTEN TP53
21 prostate cancer 29.6 EGFR MIR149 MIR21 MIR210 MIR221 MTOR
22 melanoma 29.5 MIR128-1 MIR137 MIR149 MIR185 MIR210 MIR221
23 pancreatic cancer 29.4 EGFR MIR155 MIR21 MIR210 MIR221 MTOR
24 leukemia, acute lymphoblastic 29.2 MIR128-1 MIR155 MIR21 MIR210 MIR221
25 ovarian cancer 29.1 EGFR MIR155 MIR21 MIR210 MIR221 PTEN
26 bladder cancer 29.1 EGFR MIR133B MIR185 MIR21 MIR221 TP53
27 breast cancer 29.0 EGFR IDH1 MIR128-1 MIR149 MIR155 MIR21
28 lung cancer 28.8 DMBT1 EGFR MGMT MIR133B MIR137 MIR155
29 hepatocellular carcinoma 28.6 EGFR IDH1 MIR132 MIR137 MIR155 MIR185
30 colorectal cancer 28.5 EGFR MGMT MIR132 MIR133B MIR137 MIR155
31 brain glioblastoma multiforme 12.6
32 glioma susceptibility 1 12.4
33 adult spinal cord glioblastoma multiforme 12.4
34 goodpasture syndrome 12.1
35 mismatch repair cancer syndrome 11.6
36 anti-basement membrane glomerulonephritis 11.5
37 glioma susceptibility 2 11.3
38 glioma susceptibility 3 11.3
39 glioma susceptibility 9 11.3
40 glioblastoma classical subtype 11.3
41 glioblastoma proneural subtype 11.3
42 glioblastoma mesenchymal subtype 11.3
43 glioblastoma neural subtype 11.3
44 hematuria, benign familial 11.0
45 membranoproliferative glomerulonephritis 11.0
46 dense deposit disease 11.0
47 glomerulonephritis 10.7
48 astrocytoma 10.7
49 hypoxia 10.5
50 brain ependymoma 10.4 EGFR TP53

Graphical network of the top 20 diseases related to Glioblastoma Multiforme:



Diseases related to Glioblastoma Multiforme

Symptoms & Phenotypes for Glioblastoma Multiforme

UMLS symptoms related to Glioblastoma Multiforme:


seizures, headache

GenomeRNAi Phenotypes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.02 EGFR MTOR
2 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
3 Decreased viability with paclitaxel GR00179-A-3 9.02 EGFR MTOR

MGI Mouse Phenotypes related to Glioblastoma Multiforme:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.43 DMBT1 EGFR MGMT PDGFRA PTEN TP53
2 respiratory system MP:0005388 9.17 EGFR IDH1 MGMT MTOR PDGFRA PTEN

Drugs & Therapeutics for Glioblastoma Multiforme

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
2
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999

Drugs for Glioblastoma Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 600)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
2
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
4 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 100286-90-6, 97682-44-5 60838
8
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
9
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
10
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 38904 498142
11
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
12
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 6055-19-2, 50-18-0 2907
13
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1 33419-42-0 36462
14
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
15
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
16
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
17
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
18
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
19
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 557795-19-4, 341031-54-7 5329102
20
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
21
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
22
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
23
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
24
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
25
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
26
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
27
chloroquine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
28
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
29
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
30
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
31
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
32
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
33
Disulfiram Approved Phase 2, Phase 3,Phase 1,Early Phase 1 97-77-8 3117
34
Copper Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 7440-50-8 27099
35
Nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
36
Valproic Acid Approved, Investigational Phase 3,Phase 2,Phase 1 99-66-1 3121
37
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
38
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
39
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
40
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
41
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
42
Povidone Approved Phase 3 9003-39-8
43
Povidone-iodine Approved Phase 3 25655-41-8
44
Dopamine Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
45
Angiotensin II Approved, Investigational Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
46
Losartan Approved Phase 3 114798-26-4 3961
47
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
48
Norepinephrine Approved Phase 3 51-41-2 439260
49
Cyproheptadine Approved Phase 3 129-03-3 2913
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 11103-57-4, 68-26-8 445354

Interventional clinical trials:

(show top 50) (show all 1404)
# Name Status NCT ID Phase Drugs
1 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Unknown status NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
2 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
3 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
4 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
5 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
6 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
7 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
8 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
9 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
10 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
11 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
12 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
13 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
14 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
15 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3 nimotuzumab
16 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
17 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
18 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
19 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
20 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
21 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
22 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
23 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
24 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
25 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
26 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
27 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
28 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
29 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
30 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
31 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
32 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
33 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3 TransMID
34 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
35 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
36 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
37 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
38 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
39 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
40 Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
41 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
42 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
43 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
44 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
45 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
46 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
47 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02685605 Phase 3 Temozolomide
48 A Study for Management of Ocular Side Effects in Subjects With Glioblastoma Receiving Depatuxizumab Mafodotin Recruiting NCT03419403 Phase 3 Steroid eye drop;Ophthalmic steroid ointment;Temozolomide;depatuxizumab mafodotin;Vasoconstrictor eye drop
49 Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma Recruiting NCT03632135 Phase 3 Chemotherapy
50 A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Recruiting NCT03025893 Phase 2, Phase 3 Sunitinib;Lomustine

Search NIH Clinical Center for Glioblastoma Multiforme

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: glioblastoma

Genetic Tests for Glioblastoma Multiforme

Anatomical Context for Glioblastoma Multiforme

MalaCards organs/tissues related to Glioblastoma Multiforme:

41
Brain, T Cells, Testes, Endothelial, Prostate, Spinal Cord, Bone

Publications for Glioblastoma Multiforme

Articles related to Glioblastoma Multiforme:

(show top 50) (show all 2418)
# Title Authors Year
1
Analyses of temporal and spatial patterns of glioblastoma multiforme and other brain cancer subtypes in relation to mobile phones using synthetic counterfactuals. ( 30384227 )
2019
2
The role of CMV in glioblastoma and implications for immunotherapeutic strategies. ( 30546954 )
2019
3
Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma. ( 30546966 )
2019
4
Tracing the Origin of Glioblastoma: Subventricular Zone Neural Stem Cells. ( 30551194 )
2019
5
Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients. ( 30472587 )
2019
6
miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma. ( 30365062 )
2019
7
MicroRNA‑876‑5p inhibits the progression of glioblastoma multiforme by directly targeting Forkhead box M1. ( 30365126 )
2019
8
Bradykinin B1 receptor contributes to interleukin-8 production and glioblastoma migration through interaction of STAT3 and SP-1. ( 30366000 )
2019
9
AHIF promotes glioblastoma progression and radioresistance via exosomes. ( 30387845 )
2019
10
Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure. ( 30388586 )
2019
11
Isolation and Culture of Glioblastoma Brain Tumor Stem Cells. ( 30324510 )
2019
12
EPH Profiling of BTIC Populations in Glioblastoma Multiforme Using CyTOF. ( 30324522 )
2019
13
Drug Delivery in an Orthotopic Tumor Stem Cell-Based Model of Human Glioblastoma. ( 30324525 )
2019
14
Preparation of superparamagnetic iron oxide/doxorubicin loaded chitosan nanoparticles as a promising glioblastoma theranostic tool. ( 30145790 )
2019
15
Hairless regulates p53 target genes to exert tumor suppressive functions in glioblastoma. ( 30191601 )
2019
16
Glioblastoma multiforme subterfuge as acute cerebral hemorrhage: A case report and literature review. ( 29844891 )
2018
17
Evaluation of the relationship of erythrocyte membrane Na+/K+-ATPase enzyme activity and tumor response to chemoradiotherapy in patients diagnosed with locally advanced nonsmall cell lung cancer and glioblastoma multiforme. ( 29970705 )
2018
18
Benzyl isothiocyanate inhibits human brain glioblastoma multiforme GBM 8401 cell xenograft tumor in nude mice in vivo. ( 29972272 )
2018
19
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. ( 29979390 )
2018
20
Venous thromboembolic complications with and without intermittent intraoperative and postoperative pneumatic compression in patients with glioblastoma multiforme using intraoperative magnetic resonance imaging. A retrospective study. ( 29859696 )
2018
21
Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. ( 29385725 )
2018
22
Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles. ( 29963263 )
2018
23
microRNAa89574 inhibits cell proliferation and invasion in glioblastoma multiforme by directly targeting zinc finger Ea89boxa89binding homeobox 1. ( 29901177 )
2018
24
Specifically Targeted Electromagnetic Fields Arrest Proliferation of Glioblastoma Multiforme U-87 Cells in Culture. ( 29848672 )
2018
25
A case of subgaleal metastasis from glioblastoma multiforme. ( 29898273 )
2018
26
Does radiation therapy increase gadolinium accumulation in the brain?: Quantitative analysis of T1 shortening using R1 relaxometry in glioblastoma multiforme patients. ( 29444157 )
2018
27
Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. ( 29953855 )
2018
28
Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. ( 29899827 )
2018
29
Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. ( 29416731 )
2018
30
Hyaluronic Acid-Modified Micelles Encapsulating Gem-C<sub>12</sub>and HNK for Glioblastoma Multiforme Chemotherapy. ( 29397747 )
2018
31
Early candidate biomarkers found from urine of glioblastoma multiforme rat before changes in MRI. ( 29372508 )
2018
32
Enhanced radiosensitization of human glioblastoma multiforme cells with phosphorylated peptides derived from Gli2. ( 29880393 )
2018
33
Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients. ( 29442128 )
2018
34
Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. ( 29387965 )
2018
35
A Rare Case of Concurrent Herpes Simplex Encephalitis and Glioblastoma Multiforme. ( 29492128 )
2018
36
Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience. ( 29889468 )
2018
37
Glioblastoma multiforme: another potential application for<sup>68</sup>Ga-PSMA PET/CT as a guide for targeted therapy. ( 29387926 )
2018
38
Reactive Astrocytes in Glioblastoma Multiforme. ( 29363044 )
2018
39
Longevity-Related Gene Transcriptomic Signature in Glioblastoma Multiforme. ( 29849920 )
2018
40
ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: a clinicopathologic study. ( 29369420 )
2018
41
Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the <i>SGK1</i> Gene Are Associated with Poorer Survival. ( 29976632 )
2018
42
Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. ( 29378529 )
2018
43
High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment. ( 29909500 )
2018
44
Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. ( 29910795 )
2018
45
CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB. ( 29415469 )
2018
46
A Non-randomized Controlled Trial of EMDR on Affective Symptoms in Patients With Glioblastoma Multiforme. ( 29892240 )
2018
47
Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme. ( 29393542 )
2018
48
Management of Elderly patients with Glioblastoma - Multiforme. ( 29376741 )
2018
49
Cancer stem cells from peritumoral tissue of glioblastoma multiforme: the possible missing link between tumor development and progression. ( 29963265 )
2018
50
Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme. ( 29952031 )
2018

Variations for Glioblastoma Multiforme

Copy number variations for Glioblastoma Multiforme from CNVD:

7 (show top 50) (show all 760)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13315 1 1 117600000 Gain Glioblastoma multiforme
2 13333 1 1 124300000 Gain Glioblastoma multiforme
3 13339 1 1 124300000 Loss Glioblastoma multiforme
4 13340 1 1 124300000 Loss Glioblastoma multiforme
5 13341 1 1 124300000 Loss Glioblastoma multiforme
6 13359 1 1 12600000 Gain Glioblastoma multiforme
7 13365 1 1 16100000 Gain Glioblastoma multiforme
8 13750 1 1 27800000 Loss Glioblastoma multiforme
9 13761 1 1 28000000 Deletion Glioblastoma multiforme
10 13763 1 1 28000000 Gain Glioblastoma multiforme
11 13775 1 1 39600000 Loss Glioblastoma multiforme
12 13792 1 1 51300000 Loss Glioblastoma multiforme
13 13822 1 1 7200000 Deletion MTHFR Glioblastoma multiforme
14 14314 1 107000000 111600000 Gain Glioblastoma multiforme
15 14414 1 107915304 108309068 amplification VAV3 Glioblastoma multiforme
16 14609 1 109636509 109651136 Fusion MYBPHL Glioblastoma multiforme
17 15403 1 115061059 115084034 Fusion CSDE1 Glioblastoma multiforme
18 16435 1 124300000 247249719 Gain Glioblastoma multiforme
19 16436 1 124300000 247249719 Gain Glioblastoma multiforme
20 16437 1 124300000 247249719 Gain Glioblastoma multiforme
21 16444 1 124300000 247249719 Loss Glioblastoma multiforme
22 16683 1 130300000 212100000 Gain ATP2B4 Glioblastoma multiforme
23 19008 1 148161834 148166860 Copy number SF3B4 Glioblastoma multiforme
24 19791 1 151370387 155734861 Gain CLK2 Glioblastoma multiforme
25 20600 1 153272923 153289968 Fusion DCST1 Glioblastoma multiforme
26 20612 1 153300000 154800000 Gain RAB25 Glioblastoma multiforme
27 21114 1 156847119 156923130 Copy number SPTA1 Glioblastoma multiforme
28 22041 1 16450831 16482564 Copy number EPHA2 Glioblastoma multiforme
29 23682 1 172900000 185800000 Gain Glioblastoma multiforme
30 24288 1 178190530 178346919 Fusion CEP350 Glioblastoma multiforme
31 25428 1 189000000 197500000 Gain Glioblastoma multiforme
32 25567 1 191357783 191486465 Fusion CDC73 Glioblastoma multiforme
33 26137 1 197500000 205300000 Amplification LRRN5 Glioblastoma multiforme
34 26138 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
35 26139 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
36 26142 1 197500000 205300000 Amplification NFASC Glioblastoma multiforme
37 26146 1 197500000 205300000 Amplificationlication HDMX Glioblastoma multiforme
38 26474 1 200429740 200554958 Truncation LGR6 Glioblastoma multiforme
39 26515 1 200858000 202110000 Copy number MDM4 Glioblastoma multiforme
40 26660 1 201942811 203355851 Amplification MDM4 Glioblastoma multiforme
41 28554 1 223214607 229308654 Gain ARF1 Glioblastoma multiforme
42 28555 1 223214607 229308654 Gain WNT3A Glioblastoma multiforme
43 29626 1 233890968 234060340 Fusion LYST Glioblastoma multiforme
44 30289 1 241700000 247249719 Amplification AKT3 Glioblastoma multiforme
45 30407 1 2429834 2447886 Fusion PANK4 Glioblastoma multiforme
46 31747 1 30500000 171200000 Gain Glioblastoma multiforme
47 32775 1 3928417 3978407 Deletion Glioblastoma multiforme
48 32899 1 4028404 6333694 Deletion AJAP1 Glioblastoma multiforme
49 32900 1 4028404 6333694 Deletion CHD5 Glioblastoma multiforme
50 33876 1 4952248 20897624 Deletion CDC42 Glioblastoma multiforme

Expression for Glioblastoma Multiforme

Search GEO for disease gene expression data for Glioblastoma Multiforme.

Pathways for Glioblastoma Multiforme

Pathways related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 EGFR MTOR PDGFRA PTEN TP53
2 12.68 EGFR MTOR PDGFRA PTEN TP53
3
Show member pathways
12.59 EGFR MTOR PDGFRA PTEN TP53
4
Show member pathways
12.55 EGFR MTOR PDGFRA PTEN TP53
5
Show member pathways
12.29 EGFR MTOR PDGFRA TP53
6
Show member pathways
12.23 EGFR MTOR PDGFRA PTEN TP53
7
Show member pathways
12.21 MIR210 MIR221 PTEN TP53
8 12.1 EGFR MIR21 MTOR TP53
9 11.92 EGFR MTOR PTEN TP53
10
Show member pathways
11.9 EGFR MTOR PDGFRA PTEN TP53
11 11.88 EGFR MIR128-1 MIR133B MIR137 MIR155 MIR21
12 11.81 EGFR MTOR PDGFRA PTEN TP53
13 11.79 MTOR PTEN TP53
14 11.68 EGFR MGMT MTOR PDGFRA PTEN TP53
15 11.65 MTOR PTEN TP53
16 11.36 EGFR PDGFRA TP53
17 11.33 MIR210 MIR221 TP53
18 11.25 EGFR IDH1 MTOR PDGFRA PTEN TP53
19 11.16 MIR128-1 MIR133B MIR221

GO Terms for Glioblastoma Multiforme

Cellular components related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 DMBT1 EGFR MIR128-1 MIR132 MIR155 MIR185
2 micro-ribonucleoprotein complex GO:0035068 9.4 MIR128-1 MIR132 MIR133B MIR137 MIR149 MIR155
3 PML body GO:0016605 9.33 MTOR PTEN TP53
4 postsynaptic cytosol GO:0099524 9.26 MTOR PTEN

Biological processes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.97 MIR137 MIR21 MIR221 PTEN TP53
2 negative regulation of gene expression GO:0010629 9.95 MIR132 MIR155 MIR185 MIR21
3 negative regulation of apoptotic process GO:0043066 9.95 EGFR MGMT MIR21 MIR221 PDGFRA PTEN
4 positive regulation of protein phosphorylation GO:0001934 9.91 EGFR MIR128-1 MIR21 MTOR
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 EGFR MIR21 MIR221 PDGFRA PTEN
6 wound healing GO:0042060 9.83 EGFR MTOR PDGFRA
7 negative regulation of cell migration GO:0030336 9.83 MIR137 MIR149 MIR21 PTEN
8 positive regulation of inflammatory response GO:0050729 9.81 EGFR MIR155 MIR21
9 response to organic cyclic compound GO:0014070 9.81 EGFR IDH1 MGMT PTEN
10 cellular response to amino acid stimulus GO:0071230 9.77 EGFR MTOR PDGFRA
11 positive regulation of fibroblast proliferation GO:0048146 9.75 EGFR MIR155 PDGFRA
12 positive regulation of epithelial to mesenchymal transition GO:0010718 9.73 MIR21 MIR221 MTOR
13 cholesterol homeostasis GO:0042632 9.73 MIR128-1 MIR132 MIR155 MIR185
14 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.71 MIR137 MIR185 PTEN
15 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.67 MIR133B MIR137 MIR21 PTEN
16 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.66 MIR155 MIR185
17 positive regulation of myotube differentiation GO:0010831 9.66 MIR133B MTOR
18 platelet-derived growth factor receptor signaling pathway GO:0048008 9.65 MIR221 PDGFRA PTEN
19 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.65 MIR133B MIR185 MIR21 MIR221 PTEN
20 regulation of protein kinase B signaling GO:0051896 9.64 MIR21 MTOR
21 negative regulation of cell size GO:0045792 9.63 MTOR PTEN
22 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.63 EGFR TP53
23 positive regulation of protein kinase B signaling GO:0051897 9.63 EGFR MIR132 MIR21 MIR221 MTOR PDGFRA
24 negative regulation of blood vessel endothelial cell migration GO:0043537 9.62 MIR132 MIR133B MIR137 MIR155
25 negative regulation of vascula